Introduction

The Trailblazer All's Four trial is a Phase III randomized trial that evaluated the potential superiority of Donanamab versus Aducanamab on patients with early symptomatic Alzheimer's disease. Dr. Natalia Roast, Chief of the Stroke Division at the Massachusetts General Hospital Department of Neurology and Professor of Neurology at Harvard Medical School, President-E lacked for the American Academy of Neurology. "I think this was just a kind of opening salvo into targeted treatment of Alzheimer's disease," she says.